CureVac N.V.

Symbol: CVAC




Market price today

  • -2.2997

    P/E Ratio

  • 0.0587

    PEG Ratio

  • 754.49M

    MRK Cap

  • 0.00%

    DIV Yield

CureVac N.V. (CVAC) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Alexander Zehnder M.B.A., M.D.
Full-time employees:904
Address:Friedrich-Miescher-Strasse 15

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

General Outlook

In simple terms, CureVac N.V. has 223.883 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep -2.516% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -7.176%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -7.050%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.359% return, is a testament to CureVac N.V.'s adeptness in optimizing resource deployment. CureVac N.V.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.484%. Furthermore, the proficiency of CureVac N.V. in capital utilization is underscored by a remarkable -0.445% return on capital employed.

Stock Prices

CureVac N.V.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $3.52, while its low point bottomed out at $3.39. This variance in figures offers investors a lucid insight into the roller-coaster ride that is CureVac N.V.'s stock market.

Liquidity Ratios

Analyzing CVAC liquidity ratios reveals its financial health of the firm. The current ratio of 356.28% gauges short-term asset coverage for liabilities. The quick ratio (324.76%) assesses immediate liquidity, while the cash ratio (308.04%) indicates cash reserves.

Current Ratio356.28%
Quick Ratio324.76%
Cash Ratio308.04%

Profitability Ratios

CVAC profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -704.83% underscores its earnings before tax deductions. The effective tax rate stands at -0.02%, revealing its tax efficiency. The net income per EBT, 100.02%, and the EBT per EBIT, 98.22%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -717.59%, we grasp its operational profitability.

Pretax Profit Margin-704.83%
Effective Tax Rate-0.02%
Net Income per EBT100.02%
EBT per EBIT98.22%
EBIT per Revenue-717.59%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.56, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a 3 cash conversion cycle and 197.15% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding325
Days of Inventory Outstanding56
Operating Cycle241.55
Days of Payables Outstanding30
Cash Conversion Cycle211
Receivables Turnover1.97
Payables Turnover11.99
Inventory Turnover6.47
Fixed Asset Turnover0.16
Asset Turnover0.05

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.22, and free cash flow per share, -1.50, depict cash generation on a per-share basis. The cash per share value, 2.09, showcases liquidity position. Lastly, the operating cash flow sales ratio, -6.38, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-1.22
Free Cash Flow per Share-1.50
Cash per Share2.09
Operating Cash Flow Sales Ratio-6.38
Free Cash Flow to Operating Cash Flow Ratio1.22
Cash Flow Coverage Ratio-6.49
Short Term Coverage Ratio-49.40
Capital Expenditure Coverage Ratio-4.45
Dividend Paid and Capex Coverage Ratio-4.45

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 5.00%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.07, we discern the balance between debt and equity financing. The long-term debt to capitalization, 5.73%, and total debt to capitalization, 6.54%, ratios shed light on its capital structure. An interest coverage of -41.31 indicates its ability to manage interest expenses.

Debt Ratio5.00%
Debt Equity Ratio0.07
Long Term Debt to Capitalization5.73%
Total Debt to Capitalization6.54%
Interest Coverage-41.31
Cash Flow to Debt Ratio-6.49
Company Equity Multiplier1.40

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.36, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.32, reflects the portion of profit attributed to each share. The book value per share, 2.82, represents the net asset value distributed per share, while the tangible book value per share, 2.65, excludes intangible assets.

Revenue Per Share0.36
Net Income Per Share-1.32
Book Value Per Share2.82
Tangible Book Value Per Share2.65
Shareholders Equity Per Share2.82
Interest Debt Per Share0.24
Capex Per Share-0.49

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -34.54%, indicates top-line expansion, while the gross profit growth, 13.78%, reveals profitability trends. EBIT growth, 39.49%, and operating income growth, 39.49%, offer insights into operational profitability progression. The net income growth, 39.51%, showcases bottom-line expansion, and the EPS growth, 40.27%, measures the growth in earnings per share.

Revenue Growth-34.54%
Gross Profit Growth13.78%
EBIT Growth39.49%
Operating Income Growth39.49%
Net Income Growth39.51%
EPS Growth40.27%
EPS Diluted Growth40.27%
Weighted Average Shares Growth1.65%
Weighted Average Shares Diluted Growth1.65%
Operating Cash Flow Growth60.96%
Free Cash Flow Growth55.94%
10-Year Revenue Growth per Share387.50%
5-Year Revenue Growth per Share387.50%
3-Year Revenue Growth per Share260.28%
10-Year Operating CF Growth per Share-259.38%
5-Year Operating CF Growth per Share-259.38%
3-Year Operating CF Growth per Share-206.27%
10-Year Net Income Growth per Share-225.33%
5-Year Net Income Growth per Share-225.33%
3-Year Net Income Growth per Share-132.06%
10-Year Shareholders Equity Growth per Share1446.89%
5-Year Shareholders Equity Growth per Share1446.89%
3-Year Shareholders Equity Growth per Share1259.50%
Receivables Growth113.13%
Inventory Growth-57.28%
Asset Growth-25.71%
Book Value per Share Growth-23.80%
Debt Growth45.67%
R&D Expense Growth-92.33%
SGA Expenses Growth0.53%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 614,104,194.271, captures the company's total value, considering both debt and equity. Income quality, 1.15, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 1.32, gauges operational efficiency, while the research and development to revenue, 92.78%, highlights investment in innovation. The ratio of intangibles to total assets, 3.69%, indicates the value of non-physical assets, and capex to operating cash flow, 32.57%, measures reinvestment capability.

Enterprise Value614,104,194.271
Income Quality1.15
Sales General and Administrative to Revenue1.32
Research and Development to Revenue92.78%
Intangibles to Total Assets3.69%
Capex to Operating Cash Flow32.57%
Capex to Revenue-138.27%
Capex to Depreciation-392.66%
Stock-Based Compensation to Revenue13.62%
Graham Number9.14
Return on Tangible Assets-30.05%
Graham Net Net1.14
Working Capital427,804,000
Tangible Asset Value501,475,000
Net Current Asset Value256,810,000
Average Receivables28,970,500
Average Payables95,254,500
Average Inventory40,074,000
Days Sales Outstanding214
Days Payables Outstanding135
Days of Inventory On Hand48

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.15, and the price to book ratio, 1.15, reflect the market's valuation relative to the company's book value. The price to sales ratio, 16.21, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -2.08, and price to operating cash flows, -2.54, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.15
Price to Book Ratio1.15
Price to Sales Ratio16.21
Price Cash Flow Ratio-2.54
Price Earnings to Growth Ratio0.06
Enterprise Value Multiple-4.04
Price Fair Value1.15
Price to Operating Cash Flow Ratio-2.54
Price to Free Cash Flows Ratio-2.08
Price to Tangible Book Ratio2.00
Enterprise Value to Sales9.11
Enterprise Value Over EBITDA-2.75
EV to Operating Cash Flow-2.15
Earnings Yield-23.32%
Free Cash Flow Yield-35.53%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of CureVac N.V. (CVAC) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -2.300 in 2024.

What is the ticker symbol of CureVac N.V. stock?

The ticker symbol of CureVac N.V. stock is CVAC.

What is company IPO date?

IPO date of CureVac N.V. is 2020-08-14.

What is company current share price?

Current share price is 3.370 USD.

What is stock market cap today?

The market cap of stock today is 754485710.000.

What is PEG ratio in 2024?

The current 0.059 is 0.059 in 2024.

What is the number of employees in 2024?

In 2024 the company has 904.